LUNG Profile
Pulmonx Corporation is a leading medical technology company specializing in minimally invasive solutions for the management and treatment of chronic obstructive pulmonary diseases (COPD). The company's flagship product, the Zephyr Endobronchial Valve, is designed to address severe emphysema by reducing hyperinflation in the lungs. This innovative valve is implanted bronchoscopically to improve lung function and quality of life for adult patients suffering from this debilitating condition. Pulmonx also offers the Chartis Pulmonary Assessment System, which includes a balloon catheter and console system equipped with flow and pressure sensors. This system is used to assess collateral ventilation, a critical factor in determining the suitability of patients for lung volume reduction therapies.
In addition to these key products, Pulmonx provides the StratX Lung Analysis Platform, a sophisticated cloud-based service that utilizes quantitative computed tomography (CT) analysis. The StratX platform delivers detailed insights into emphysema destruction, fissure completeness, and lobar volume. This data is crucial for identifying target lobes for treatment with the Zephyr Endobronchial Valves, thereby enhancing the precision and effectiveness of the therapy. The platform's advanced analytics support clinicians in making informed decisions about patient care and treatment planning.
Pulmonx Corporation serves a global patient base, with its products and services available in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company's international reach underscores its commitment to improving patient outcomes through innovative medical technologies. Pulmonx's solutions are designed to address the significant challenges associated with COPD and emphysema, offering patients and healthcare providers effective options for managing these chronic conditions.
Originally incorporated in 1995 and known simply as Pulmonx, the company rebranded as Pulmonx Corporation in December 2013 to better reflect its expanded focus and growing global presence. Headquartered in Redwood City, California, Pulmonx continues to drive advancements in pulmonary medicine with its cutting-edge technologies and commitment to enhancing patient care. The company's ongoing innovations and international operations position it as a key player in the field of respiratory healthcare.
|
